

# Yves Allory

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5041391/publications.pdf>

Version: 2024-02-01

32  
papers

1,681  
citations

567281

15  
h-index

454955

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2235  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. <i>Journal of Clinical Pathology</i> , 2023, 76, 126-132.  | 2.0 | 7         |
| 2  | The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.  | 0.8 | 1         |
| 3  | Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer. <i>Journal of Pathology</i> , 2022, 256, 108-118.  | 4.5 | 12        |
| 4  | Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2013-2022.   | 1.6 | 75        |
| 5  | Overexpression of Nucleolin and Associated Genes in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4491.   | 4.1 | 7         |
| 6  | BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .   | 8.2 | 11        |
| 7  | Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. <i>European Urology</i> , 2021, 79, 214-221.               | 1.9 | 130       |
| 8  | Risk factors associated with positive surgical marginsâ€™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.  | 2.2 | 22        |
| 9  | ClasificaciÃ³n de los tumores testiculares. <i>EMC - UrologÃ­a</i> , 2021, 53, 1-15.  | 0.0 | 0         |
| 10 | Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 554-562.  | 1.9 | 6         |
| 11 | A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.  | 1.9 | 741       |
| 12 | Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100536. | 1.1 | 13        |
| 13 | Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. <i>Cancers</i> , 2020, 12, 763.   | 3.7 | 22        |
| 14 | High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRILâ€™ARF Bidirectional Promoter. <i>Non-coding RNA</i> , 2019, 5, 44.   | 2.6 | 21        |
| 15 | Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.   | 2.8 | 16        |
| 16 | Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis. <i>Life Science Alliance</i> , 2019, 2, e201900449.  | 2.8 | 12        |
| 17 | Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. <i>Modern Pathology</i> , 2018, 31, 1270-1281.   | 5.5 | 24        |
| 18 | Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). <i>World Journal of Urology</i> , 2018, 36, 1643-1649.   | 2.2 | 25        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization. <i>Translational Andrology and Urology</i> , 2018, 7, 757-759.  | 1.4  | 4         |
| 20 | Ductal adenocarcinoma of the prostate: Clinical and biological profiles. <i>Prostate</i> , 2017, 77, 1242-1250.   | 2.3  | 26        |
| 21 | Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e45-e52.                     | 1.9  | 12        |
| 22 | Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.   | 2.5  | 52        |
| 23 | Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316.  | 1.2  | 49        |
| 24 | Validation of VEGFR rs9582036 as predictive biomarker in metastatic clear cell renal cell carcinoma patients treated with sunitinib. <i>BJU International</i> , 2016, 118, 890-901.   | 2.5  | 23        |
| 25 | Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. <i>Oncotarget</i> , 2016, 7, 69397-69411.  | 1.8  | 17        |
| 26 | Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.  | 3.9  | 0         |
| 27 | EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.   | 12.4 | 304       |
| 28 | Long-term results and prognostic factors for survival following adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French retrospective multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4549-4549. | 1.6  | 0         |
| 29 | Kidney Cancer Pathology in the New Context of Targeted Therapy. <i>Pathobiology</i> , 2011, 78, 90-98.  | 3.8  | 23        |
| 30 | Parafibromin as a new immunohistochemistry staining to improve pathologic diagnosis of renal oncocytoma: Analysis of 225 renal tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 408-408.  | 1.6  | 1         |
| 31 | Identification of a Novel Biomarker Signature Associated with Risk for Bone Metastasis in Patients with Renal Cell Carcinoma. <i>International Journal of Biological Markers</i> , 2010, 25, 112-115.   | 1.8  | 10        |
| 32 | Reply to S. Zeng et al. <i>Journal of Clinical Oncology</i> , 0, , .  | 1.6  | 1         |